Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals

NCT04368728 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

46969

Enrollment

INDUSTRY

Sponsor class

Conditions

SARS-CoV-2 Infection
COVID-19

Interventions

BIOLOGICAL: BNT162b1
BIOLOGICAL: BNT162b2
OTHER: Placebo
BIOLOGICAL: BNT162b2SA

Sponsor

BioNTech SE

Collaborators

[object Object]